Table 1.

Characteristics of randomized controlled trials included in the meta-analysis

PD-1 inhibitor armControl arm
ReferencePhaseCancer typeDrugSafety follow-up (months)Number of patientsAll-grade pneumonitisGrade ≥ 3 pneumonitisPneumonitis-related deathDrugSafety follow-up (month)Number of patientsAll-grade pneumonitisGrade ≥ 3 pneumonitisPneumonitis-related death
Borghaei et al, 2015IIINSCLCNivolumab6.3287830Docetaxel6.3268110
Brahmer et al, 2015IIINSCLCNivolumab7.3131610Docetaxel5.6129000
Ferris et al, 2016IIIHead and neckNivolumab5.2236521Methotrexate, docetaxel, or cetuximab5.2111100
Herbst et al, 2016IIINSCLCPembrolizumab6.568226123Docetaxel5.0309310
Hodi et al, 2016IIIMelanomaNivolumab and ipilimumab6.3941031Ipilimumab6.346000
Langer et al, 2016aIINSCLCPembrolizumab, carboplatin, and pemetrexed1159310Carboplatin and pemetrexed7.962000
Larkin et al, 2015IIIMelanomaNivolumab10.8313410Ipilimumab6.3311510
Nivolumab and ipilimumab6.33132030
Reck et al, 2016aIIINSCLCPembrolizumab10154940Platinum-based chemotherapy6.8150110
Ribas et al, 2015aIIMelanomaPembrolizumab7.3357620Chemotherapy5171000
Robert et al, 2015IIIMelanomaNivolumabNR206300DacarbazineNR205000
Robert et al, 2015aIIIMelanomaPembrolizumab8.3b555610Ipilimumab4.7b256110
Weber et al, 2015IIIMelanomaNivolumab8.6268500Chemotherapy5.3102000
  • Abbreviation: NR, not reported.

  • aPneumonitis reported regardless of attribution to study treatment by the investigator.

  • bMean safety follow-up time.